The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SAN DIEGO, July 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo ...
Google first began pushing out a new company logo about a year ago. The new logo brought us a gradient style that blended its iconic colorway together, which Google explained as having something to do ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced ...
Pokémon turns 30 this year, and The Pokémon Company is celebrating that milestone in all number of ways, including creating a special 30th anniversary logo for every individual Pokémon. That's right, ...
With Super Bowl LX officially in the books following Seattle's win over New England, the NFL has already started looking ahead to Super Bowl LXI by unveiling the logo for next year's game. The league ...
Logos has plans to begin deploying satellites in late 2027 Credit: Logos Space Services TAMPA, Fla. — Logos Space Services has secured U.S. regulatory approval to deploy up to 4,178 low Earth orbit ...
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: ...
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases. The drugmaker will pay $14.50 per share for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results